Publications
Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives KU Leuven
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial Institute of Tropical Medicine Hasselt University KU Leuven Vrije Universiteit Brussel
BACKGROUND: The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide antibiotic, known for its immunomodulatory properties. It has shown antiviral effect specifically against SARS-CoV-2 in vitro and acts on cytokine signaling ...
Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-ofconcept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial Hasselt University KU Leuven
Herpes simplex virus resistance to antivirals KU Leuven
Belgian experience with direct acting antivirals in people who inject drugs Hasselt University University of Antwerp Ghent University KU Leuven
The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience Hasselt University Ghent University University of Antwerp KU Leuven
Belgian Experience with Direct Acting Antivirals in People Who Inject Drugs. Hasselt University KU Leuven
Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients Vrije Universiteit Brussel
BACKGROUND: New direct-acting antivirals agents (DAAs) are very safe and well tolerated.
OBJECTIVES: The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and are on chronic medications.
STUDY DESIGN: All HCV-infected patients over 65 years old in clinical follow-up at two Hospitals in Spain who initiated anti-HCV therapy were included (August 2012-October ...